No profile data available.
Avenue Therapeutics, Inc. (ATXI) is a healthcare company in the opioid pain relief pharmaceuticals industry, based in Bay Harbor Islands, United States, with about 1 full-time employees.
It reported revenue of $1.40 million for fiscal year 2025, and net income of -$2.91 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $0. Its market capitalization was $1.42 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include ATX-04, a small molecule therapy for the treatment of Pompe disease; and intravenous tramadol, a schedule IV opioid to treat post-operative acute pain.
Avenue Therapeutics reported $1.40 million in revenue for fiscal year 2025. In Q1 2026 revenue was $0.
$1.42 million as of October 9, 2026.
Listed companies of a similar size in the same industry (opioid pain relief pharmaceuticals) include Collegium Pharmaceutical, Inc. (COLL), Ensysce Biosciences, Inc. (ENSC), Trevena, Inc. (TRVN).